Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. The aim is to provide potential new therapies for patients with difficult to treat lung and gastrointestinal cancers.
“We are excited to partner with Enara Bio as part of our mission to bring transformative new treatments to cancer patients,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research, Boehringer Ingelheim. “We are advancing a unique pipeline of cancer cell-directed agents, immuno-oncology therapies and intelligent combination approaches to help combat cancer. Enara Bio’s unique discovery platform offers a novel and highly differentiated approach that will allow us to look beyond the known proteome to identify and characterize Dark Antigens to support the development of T-Cell Receptor (TCR)-directed immunotherapies and therapeutic vaccines. We believe this is a highly innovative and promising approach to the development of the next wave of cancer immunotherapies.”
Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™) will be used to discover and validate novel Dark Antigens in up to three tumor types in the lung and gastrointestinal cancer space. The discovery of shared antigens could lead to the development of vaccines that can be readily utilized to help a broader group of cancer patients.
Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic dark matter, or the portion of the human genome that is normally not expressed as protein. Dark Antigen-encoding sequences are usually silenced in healthy cells but are activated and presented on tumor cells. They are associated with specific cancer types and, importantly, are shared across patients. Since typically not visible to the immune system, they represent a large potential repertoire of novel antigens that can be developed as targets for new immunotherapies.
“We are extremely pleased to enter this strategic licensing agreement, our first major deal leveraging our pioneering Dark Antigen discovery and validation capabilities,” said Kevin Pojasek, President and CEO of Enara Bio. “Boehringer Ingelheim is an innovation-led company dedicated to producing breakthrough treatments with a significant focus on cancer. We are excited to build this relationship and are encouraged that Boehringer Ingelheim shares our view of the potential of Dark Antigens to be a source of important and unconventional targets for novel cancer immunotherapies. This agreement provides strong validation for our science and our approach to exploiting the cancer-associated antigenic repertoire derived from genomic dark matter and we look forward to a productive collaboration.”
This collaboration with Enara Bio is the latest of several strategic partnerships and acquisitions for Boehringer Ingelheim to build its cancer vaccine platform and provides important validation for Enara Bio’s Dark Antigen platform. The past acquisitions of ViraTherapeutics and AMAL Therapeutics’ vaccine modalities coupled with Enara Bio’s capabilities position Boehringer Ingelheim to develop sophisticated virus and vaccine modalities for its prime/boost vaccine platform.
Under the agreement, Boehringer Ingelheim has the option to license Dark Antigens discovered and validated by Enara Bio. Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer immunotherapies, including therapeutic vaccines and T-cell redirecting biologics. Enara Bio retains rights to use any discovered antigens for use in cell therapy-based products.
Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/strategic-collaboration-enarabio
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005444/en/
Contact information
Media Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: 49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: 203-791-6672
press@boehringer-ingelheim.com
Enara Bio
Enara Bio Limited
Kevin Pojasek, CEO
P: +44(0)1865 504 994
info@enarabio.com
Citigate Dewe Rogerson
Mark Swallow, Frazer Hall, Nathaniel Dahan
P: +44 (0)20 7638 9571
enarabio@citigatedewerogerson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frontgrade’s Next-Generation SADA-10 Enhances Satellite Power System Efficiency for LEO and MEO Missions19.11.2025 14:30:00 EET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions,today announced the SADA-10, a compact Solar Array Drive Assembly (SADA) engineered to deliver precise, reliable solar array positioning for Low and Medium Earth Orbit missions. Designed with the latest technology for New Space and leveraging Frontgrade learnings from heritage systems, the SADA-10 combines flight-proven reliability with optimized size, weight, power, and cost (SWaP-C) to give customers greater efficiency and mission assurance in a smaller footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119865921/en/ The SADA-10’s hybrid stepper motor and harmonic gear drive provide high torque output, zero backlash, and accuracy of 0.015°, ensuring precise solar tracking and maximum power generation in orbit. Dual potentiometers enable redundant position sensing for reliable performance,
Frontgrade Unveils RT-SADE: Precision Motor Control for Next-Gen Space Missions19.11.2025 14:00:00 EET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the RT-SADE (Radiation-Tolerant Solar Array Drive Electronics), a next-generation microprocessor-based stepper motor controller engineered to deliver precision, reliability, and versatility for demanding spacecraft and defense applications. Designed for mission-critical motion control systems such as solar array drives, RT-SADE combines radiation-tolerant electronics, advanced fault management, and flexible configuration options to give customers superior performance and confidence in the harshest environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119546361/en/ Built around a microprocessor and advanced circuitry rated to 30 krad total ionizing dose, RT-SADE ensures long-term durability and mission assurance for Low- to Medium-Earth Orbit (LEO/MEO) operati
Murata Named Top Innovator for UltraSonic Clearing Device Technology Advancing All-Weather ADAS19.11.2025 14:00:00 EET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has been selected as a Top Innovator in the Digital category of the CLEPA Innovation Awards. The award recognizes Murata’s UltraSonic Clearing Device (USCD) technology, which is currently in development to augment the effectiveness of cameras and sensors used in advanced driver assistance systems (ADAS) and autonomous driving applications, regardless of weather conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119372516/en/ [Murata Manufacturing Co., Ltd.] CLEPA While current camera and sensor technologies often rely on ideal operating conditions, their performance can be negatively impacted by rain, fog, dust, ice, and snow. Murata’s USCD technology is addressing this challenge by using ultrasonic vibrations to disperse water and remove debris from the camera lens and sensor, maintaining visibility. The ultrasonic vibrations also heat the outer le
CMOs Face a ‘Reputation and Results’ Reckoning, According to NIQ’s 2026 Outlook19.11.2025 13:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its CMO Outlook: Guide to 2026 report, revealing how chief marketing officers (CMOs) are navigating a critical inflection point between brand building and revenue accountability. According to the report, 83% of CMOs remain confident in their brand’s equity, even as they face tightening budgets and heightened scrutiny over ROI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118947080/en/ NIQ CMO Outlook: Guide to 2026 “Every marketing dollar is now under the microscope,” said Marta Cyhan-Bowles, Chief Communications Officer & Head of Global Marketing COE, NIQ. “With organizations prioritizing cost reductions, CMOs are being challenged not just to spend wisely, but to prove how marketing directly drives awareness, growth, and loyalty. It’s no longer just about efficiency; it’s about proving impact – all with largely flat budgets.” Key Findings f
Data Space Technology Leaders Advance Data Interoperability in Construction and Real Estate at the Gaia-X Summit19.11.2025 12:03:00 EET | Press release
Leaders in data space technology are converging at the Gaia-X Summit, in Porto November 20-21, to address the imperative of interoperability within and across data spaces in the construction and real estate sectors. The main objective is to assess how data spaces can leverage the world’s estimated $393 trillion in real estate assets. Achieving this involves exploring numerous use cases among the entire building lifecycle, from design to demolition, including construction, renovation and facility management operations, which creates a win-win situation for both industry and technology stakeholders. In France, the construction and renovation market alone is estimated at €200 billion annually. Designed to address the sector’s challenges, Digital TER-X is a technology demonstrator serving the construction and real estate use cases. Its relevance has been recognized, notably by being named in November 2025 Gaia-X Lighthouse Project, just one year after its Gaia-X Endorsed Project status, an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom